Halopemide (Standard)

Halopemide (Standard) is the analytical standard of Halopemide. This product is intended for research and analytical applications. Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].

Product Specifications

CAS Number

[59831-65-1]

UNSPSC

12352100

Target

Dopamine Receptor; Phospholipase; Reference Standards

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Field of Research

Cancer; Neurological Disease

Smiles

O=C(C1=CC=C(C=C1)F)NCCN2CCC(CC2)N3C4=CC=C(C=C4NC3=O)Cl

Molecular Formula

C21H22ClFN4O2

Molecular Weight

416.88

References & Citations

[1]Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5 (2) :108-17.|[2]Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl) . 1981;75 (3) :254-7.|[3]Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234 (4) :4825-4839.